Research programme: hepatitis B virus inhibitors - BayerAlternative Names: Hepatitis B virus inhibitors research programme - Bayer
Latest Information Update: 08 Nov 2006
At a glance
- Originator Bayer
- Mechanism of Action Hepatitis B virus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Hepatitis B treatment in Germany (unspecified route)
- 06 Dec 2002 Preclinical trials in Hepatitis B treatment in Germany (unspecified route)